PLANTATION, Fla.--(BUSINESS WIRE)--Dr. Armitage is internationally recognized as a leading expert on non-Hodgkin lymphoma, and has played a critical role in advancing bone marrow transplantation. He is the recipient of many national and international awards, most recently receiving ASCO’s 2014 Special Recognition Award. The Special Recognition Award honors individuals who have made major contributions in areas of clinical oncology, cancer research, clinical trials, reimbursement, and patient advocacy activities and who have given long-term service to clinical oncology.
Dr. Armitage is presently a member of the Journal of Clinical Oncology editorial board and is editor of The ASCO Post. He is the Joe Shapiro Professor of Medicine at the University of Nebraska Medical Center, where he focuses on patient care, and helping students, residents, and fellows become more involved with clinical research and writing.
He serves on several national and international committees and served as President of ASCO (1996-97) and President of ASBMT (2000-01). He has authored or co-authored more than 500 articles, 95 book chapters, more than 450 abstracts, and is the editor/co-editor of 24 books.
“We are deeply honored to have Dr. Armitage join Oncology Analytics’ Distinguished Academic Advisory Board,” stated Marc Fishman, MD, CEO and Chief Medical Officer at Oncology Analytics. “We are confident his deep clinical expertise and many contributions to advancing knowledge in oncology will support our efforts to promote and reinforce value-based cancer care, and will complement our other distinguished clinical leaders on this Advisory Board.”
About Oncology Analytics, Inc.
Oncology Analytics provides chemotherapy decision support services and technology solutions used by more than 4,000 physicians and covering more than 1.5 million members for national health plans. Through clinical research, patented technology and physician-centric customer services, OA ensures treating oncologists have the information they need to deliver the most efficacious, least toxic and most affordable chemotherapy treatments available to their patients. Inc. magazine’s 2013 Inc 500|5000 list named OA the 18th fastest growing private companies in the United States health sector.